Brighton Jones LLC increased its stake in shares of Celgene Corporation (NASDAQ:CELG) by 3.2% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 7,797 shares of the biopharmaceutical company’s stock after buying an additional 242 shares during the quarter. Brighton Jones LLC’s holdings in Celgene Corporation were worth $1,013,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in CELG. Harel Insurance Investments & Financial Services Ltd. purchased a new position in shares of Celgene Corporation during the first quarter worth about $118,000. Penserra Capital Management LLC purchased a new position in shares of Celgene Corporation during the second quarter worth about $129,000. Acropolis Investment Management LLC purchased a new position in shares of Celgene Corporation during the second quarter worth about $144,000. Mitsubishi UFJ Securities Holdings Co. Ltd. grew its holdings in shares of Celgene Corporation by 47.5% during the first quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 1,180 shares of the biopharmaceutical company’s stock worth $147,000 after buying an additional 380 shares during the last quarter. Finally, Rational Advisors LLC purchased a new position in shares of Celgene Corporation during the second quarter worth about $156,000. 79.39% of the stock is currently owned by hedge funds and other institutional investors.
A number of research firms recently issued reports on CELG. Oppenheimer Holdings, Inc. reissued an “outperform” rating and set a $175.00 price target (up previously from $148.00) on shares of Celgene Corporation in a report on Monday, July 31st. Cantor Fitzgerald set a $160.00 price target on Celgene Corporation and gave the stock a “buy” rating in a report on Thursday, July 27th. William Blair reissued an “outperform” rating on shares of Celgene Corporation in a report on Friday, October 20th. BMO Capital Markets reissued an “outperform” rating and set a $160.00 price target (up previously from $152.00) on shares of Celgene Corporation in a report on Friday, July 28th. Finally, Leerink Swann reissued a “buy” rating and set a $156.00 price target on shares of Celgene Corporation in a report on Friday, October 20th. One research analyst has rated the stock with a sell rating, twelve have issued a hold rating, nineteen have issued a buy rating and two have assigned a strong buy rating to the stock. Celgene Corporation presently has an average rating of “Buy” and a consensus target price of $139.64.
In other Celgene Corporation news, Director Ernest Mario sold 18,506 shares of the stock in a transaction that occurred on Thursday, August 10th. The shares were sold at an average price of $130.52, for a total value of $2,415,403.12. Following the completion of the sale, the director now owns 69,424 shares in the company, valued at approximately $9,061,220.48. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Michael D. Casey sold 9,250 shares of the stock in a transaction that occurred on Tuesday, September 5th. The stock was sold at an average price of $139.03, for a total transaction of $1,286,027.50. Following the completion of the sale, the director now owns 9,250 shares of the company’s stock, valued at approximately $1,286,027.50. The disclosure for this sale can be found here. In the last 90 days, insiders sold 38,733 shares of company stock valued at $5,259,359. 0.95% of the stock is owned by insiders.
Celgene Corporation (NASDAQ:CELG) last issued its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.87 by $0.04. The business had revenue of $3.29 billion during the quarter, compared to the consensus estimate of $3.42 billion. Celgene Corporation had a net margin of 27.36% and a return on equity of 63.80%. The firm’s quarterly revenue was up 10.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.58 EPS.
About Celgene Corporation
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
What are top analysts saying about Celgene Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Celgene Corporation and related companies.